Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Value in Oncology
Cost of Surgery Comparable to Nonsurgical Options in Advanced-Stage Oropharynx Cancer
By
Meg Barbor, MPH
Value in Oncology
May 2016, Vol 7, No 4
Surgery for the primary treatment of T1-T3 oropharynx squamous-cell carcinoma (OPC) does not increase the cost of care, even for patients requiring adjuvant treatment, according to A. Daniel Pinheiro, MD, an otolaryngologist at Mercy Clinic Ear, Nose, and Throat-Surgery Center, Springfield, MO, who presented his findings at the 2016 Multidisciplinary Head and Neck Cancer Symposium.
Read Article
Adverse Events Associated with Tyrosine Kinase Inhibitors Carry High Economic Burden
By
Chase Doyle
Value in Oncology
May 2016, Vol 7, No 4
A study using the FDA Adverse Event Reporting System (FAERS) has demonstrated the high cost burden of adverse events (AEs) associated with the use of tyrosine kinase inhibitors (TKIs) in patients with chronic myelogenous leukemia (CML). The results were presented at ASH 2015 by Nicola Wallis, MRCPath, FFPM, Bristol-Myers Squibb, Princeton, NJ.
Read Article
OPT-IN Pilot Project Increases Clinician Understanding of Treatment Prices
By
Meg Barbor, MPH
Value in Oncology
May 2016, Vol 7, No 4
Read Article
Impact of Financial Toxicity on Health-Related Quality of Life
By
Chase Doyle
Value in Oncology
April 2016, Vol 7, No 3
Researchers in Chicago have developed a financial toxicity grading system based on clinically meaningful changes in health-related quality of life. According to lead investigator Jonas A. de Souza, MD, Assistant Professor of Medicine, University of Chicago, at the 2016 Cancer Survivorship Symposium, the tool has been validated in 2 separate cohorts of patients with cancer, with plans for a larger, prospective study underway.
Read Article
Improving Value by Understanding the Total Cost of Cancer Care
By
Meg Barbor, MPH
Value in Oncology
April 2016, Vol 7, No 3
The use of cost data to inform infrastructure investments can help cancer centers move toward value-based payment models, improve end-of-life planning, and reduce futile care, according to Kerin B. Adelson, MD, Chief Quality Officer and Deputy Chief Medical Officer, Smilow Cancer Hospital (SCH) at Yale-New Haven, CT.
Read Article
Cost of Care Not Linked to Improved Survival for Elderly Patients with Myelodysplastic Syndromes
By
Chase Doyle
Value in Oncology
April 2016, Vol 7, No 3
A study of state-specific costs of care and survival among Medicare beneficiaries with myelodysplastic syndromes (MDS) shows no correlation between the cost of care and patient outcomes.
Read Article
ASCO’s 2016 State of Cancer Report: Delivering High-Value Quality Care Remains Elusive
By
Alice Goodman
Value in Oncology
April 2016, Vol 7, No 3
On January 16, 2016, President Barack Obama promised a “moonshot” to accelerate national progress to combat cancer, but delivering on that promise faces many challenges.
Read Article
Measuring Value in Healthcare to Improve Quality
By
Chase Doyle
Economics & Value
,
Value in Oncology
February 2016, Vol 7, No 1
Medicare is poised to incorporate new quality metrics as a guide for payments. At ASH 2015, Helen Burstin, MD, MPH, Chief Scientific Officer, National Quality Forum, Washington, DC, discussed the need for measures and reporting systems that reflect patient care and care coordination.
Read Article
Redesigning the Payment Model for Acute Leukemia: Benefits and Challenges of the Episode-of-Care Model
By
Chase Doyle
Value in Oncology
February 2016, Vol 7, No 1
Given the high cost of care for acute leukemia, innovative payment strategies that reward longitudinal care and create economic incentives for data-driven care delivery are needed, according to Joseph Alvarnas, MD, Director of Value-Based Analytics, and Associate Clinical Professor of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.
Read Article
Value-Based Purchasing: Implications for Hematology
By
Chase Doyle
Value in Oncology
,
Value-Based Care
February 2016, Vol 7, No 1
Medicare has initiated several programs in the past decade to encourage value, but questions remain regarding their effectiveness. At ASH 2015, Andrew Ryan, PhD, MA, Associate Professor of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor, addressed the implications of using financial incentives to drive care quality and reduce cost.
Read Article
Page 5 of 7
1
2
3
4
5
6
7
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma